Abstract:Treating HIV is made difficult by the evolution of antimicrobial resistant mutants of that occurs in the life cycle of this virus. This has led to the evolution of numerous inhibition mechanism that intends to challenges the replication of this virus. One such approach is the application of molecular modelling in drug discovery. In this study the application of computer aided drug design were employed in finding an inhibitor that can contribute in finding a suitable drug candidate. Firstly, the ZINC database was screened using the Lipinski’s rule of five, and compounds having similar biological features were classified and grouped together into a compound library. Secondly, the co-crystallized structure of 1rv7 wild type of HIV-1 protease was used to construct a pharmacophore model that was used to screen further, the ZINC database Ligand stored in the compound library. Thestructure-basedpharmacophore was created by mimicking the three main active features of the co-crystallized structure from the Protein Data Bank, namely, 82 and 84, I50 and I150 residues.Thirdly, a total of twenty-six of the compounds that had less than 0,5 RMSD were identified and selected. Fourthly, based on the best docking ligands, ten of these compounds having high binding affinity were selected. These compounds are ZINC_001456687980 (-8.0), ZINC_001445792073 (-7.8) and ZINC_001461099137 (-7.4), successively. However, ZINC_001461099137 was eliminated based on unfavorable donor-donor interaction. The subsequent compound, ZINC_000015276352 was then placed on the top three leading compounds with a binding affinity of (-6.9). Fifthly, the ADMET property analysis was used on the top ten compounds, and the compounds that satisfied the analysis were, ZINC_001456687980, ZINC_000015276352, ZINC_001359888321 and ZINC_001460445290. The main properties that included the BBB permeation, the gastrointestinal absorption, pan assay interference structure (PAINS), were analyzed. ZINC_001456687980 had two violation (mw >350, XLOGP3>3.5),whiles ZINC_000015276352 had three violations (mw > 350, XLOGP3 > 3.5, rotatable > 7). Lastly, only two top compound underwent molecular dynamics simulations. Molecular dynamics simulation revealed the formation of numerous bond interactions between ZINC_001456687980 and ZINC_000015276352 together with the target protein.

Multistage virtual screening and identification of novel HIV-1 protease inhibitors by integrating SVM, shape, pharmacophore and docking methods

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Using Hierarchical Virtual Screening To Combat Drug Resistance Of The Hiv-1 Protease

Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification

Evaluation of Novel HIV-1 Protease Inhibitors with DRV-resistance by Utilizing 3D-QSAR Molecular Docking and Molecular Dynamics Simulation

Unveiling Novel HIV-1 Protease Inhibitors Through an Integrated Analysis of 3D-QSAR, Molecular Docking, and Binding Free Energy

Virtual Screening, Biological Evaluation, And 3d-Qsar Studies Of New Hiv-1 Entry Inhibitors That Function Via The Cd4 Primary Receptor

Structure-based virtual screening, ADMET profiling, and molecular dynamics simulation studies on HIV-1 protease for identification of active phytocompounds as potential anti-HIV agents

Identification of ZINC inhibitors for HIV-1 Protease through Structure-Based Pharmacophore, Virtual Screening, ADMET and Molecular Dynamics Simulation

Discovery of Novel Pim-1 Kinase Inhibitors by a Hierarchical Multistage Virtual Screening Approach Based on SVM Model, Pharmacophore, and Molecular Docking.

High-throughput Screening Using Pseudotyped Lentiviral Particles: a Strategy for the Identification of HIV-1 Inhibitors in a Cell-Based Assay.

New strategy for identifying potential natural HIV-1 non-nucleoside reverse transcriptase inhibitors against drug-resistance: an in silico study

An Enhanced Hybrid Screening Approach to Identify Potent Inhibitors for the SARS-CoV-2 Main Protease From the NCI Compound Library

Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach

Virtual screening with AutoDock Vina and the common pharmacophore engine of a low diversity library of fragments and hits against the three allosteric sites of HIV integrase: participation in the SAMPL4 protein–ligand binding challenge

Identification of new potential HIV-1 reverse transcriptase inhibitors by QSAR modeling and structure-based virtual screening

Discovery of Inhibitors to Block Interactions of HIV-1 Integrase with Human LEDGF/p75 Via Structure-Based Virtual Screening and Bioassays.

Identifying 124 new anti-HIV drug candidates in a 37 billion-compound database: an integrated approach of machine learning (QSAR), molecular docking, and molecular dynamics simulation

Modeling Studies of Peptide Inhibitors for the HIV Protease

Prediction of HIV‐1 Protease Inhibitors Using Machine Learning Approaches

High-throughput Screening and Experimental Identification of Potent Drugs Targeting SARS-CoV-2 Main Protease